Current progress in the gene therapy of cancer

Current Opinion in Oncology

Volumn 8, Issue 6, 1996, Pages 499-508

  Davis, Brian M ^a   Koc, Omer N ^a   Lee, Keunmyoung ^a   Gerson, Stanton L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTINEOPLASTIC AGENT; B7 ANTIGEN; CARMUSTINE; CYTOKINE; CYTOSINE DEAMINASE; CYTOTOXIC AGENT; DEOXYCYTIDINE; DIHYDROFOLATE REDUCTASE; DOXORUBICIN; FLUCYTOSINE; FLUOROURACIL; GAMMA INTERFERON; GANCICLOVIR; GLUTATHIONE TRANSFERASE; GLYCOPROTEIN P; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 7; METHOTREXATE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NITROSOUREA DERIVATIVE; PRODRUG; PROTEIN P21; PROTEIN P53; THYMIDINE KINASE; TRIMETREXATE; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

CANCER THERAPY; DRUG ACTIVATION; GENE THERAPY; GENE TRANSFER; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNOGENICITY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; TUMOR SUPPRESSOR GENE;

EID: 0029903999     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199611000-00010     Document Type: Review

References (86)

1. Moolten FL: Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986, 46:5276-5281.
2. Davidson RL, Kaufman ER, Crumpacker CS, Schnipper LE: Inhibition of herpes simplex virus transformed and untransformed cells by acycloguanosine: mechanism of uptake and toxicity. Virology 1981, 113:9-19.
3. Elion GB, Furman PA, Fyfe JA, de Miranda P, Beauchamp L, Schaeffer HJ: Selectivity of action of an antiherpetic agent 9-(2-hydroxyethoxymethyl) guanine. Proc Natl Acad Sci U S A 1977, 74:5716-5720.
4. Culver KW, Ram Z, Wallbridge S, Ishu H, Oldfield EH, Blaese RM: In vivo gene transfer with retroviral vector producer cells for treatment of experimental brain tumors. Science 1992, 256:1550-1552.
5. Bi WL, Parysek LM, Warnick R, Stambrook PJ: In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum Gene Ther 1993, 4:725-731.
6. Freeman SM, Ramesh R, Marrogi AJ: In vivo studies on the mechanism of the "bystander effect" Cancer Gene Ther 1994, 4:326.
7. Chan SH, Chen XHL, Wang Y, Kosai KI, Finegold MJ, Rich SS, Woo SL: Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995, 92:2577-2581.
8. O'Malley BWJ, Cope KA, Chen SH, Li D, Schwartz MR, Woo SLC: Combination gene therapy for oral cancer In a murine model. Cancer Res 1996, 56:1737-1741. Preclinical head and neck cancer model demonstrating the feasibility and effectiveness of using adenoviral gene therapy to induce tumor immunity using HSV-tk and interleukin-2 overexpression.
9. Santodonato L, Ferrantini M, Gabriele L, Proietti E, Venditti M, Musiani P, Modesti A, Modica A, Lupton SD, Belardelli F: Cure of mice with established metastatic friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther 1996, 7:1-10.
10. Barba D, Hardin J, Sadelain M, Gage FH: Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci U S A 1994, 91:4348-4352.
11. Vile RG, Hart IR: Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res 1993, 53:3860-3864.
12. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR: Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994, 54:6228-6234. Effective and tumor-specific treatment of micrometastatic disease with intravenous injection of a retrovirus encoding HSV-tk.
13. Ido A, Nakata K, Kato Y, Nakao K, Murata K, Fujita M, Ishii N, Tamaoki T, Shiku H, Nagataki S: Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of human α-fetoprotein gene promoter. Cancer Res 1995, 55:3105-3109.
14. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K-H, Ishitobi M, Omata M: Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res 1996, 56:1341-1345.
15. Sugaya S, Fujita K, Kikuchi A, Ueda H, Takakuwa K, Kodama S, Tanaka K: Inhibition of tumor growth by direct intratumoral gene transfer of herpes simplex virus thymidine kinase gene with DNA-liposome complexes. Hum Gene Ther 1996, 7:223-230.
16. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA: In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res 1993, 53:4619-4626.
17. Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE: Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995, 55:4808-4812. Direct comparison of two different suicide genes for their efficiency and bystander effects.
18. Mullen CA, Coale MM, Lowe R, Blaese RM: Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumors. Cancer Res 1994, 54:1503-1506.
19. Mullen CA, Petropoulos D, Lowe RM: Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res 1996, 56:1361-1366. Excellent series of experiments exploring the use of tumor vaccines expressing cytosine deaminase and interleukin-6 in the treatment of metastatic cancer.
20. Chen L, Waxman DJ, Chen D, Kufe DW: Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome p450 gene. Cancer Res 1996, 56:1331-1340.
21. Hapke KM, Stegmann APA, Mitchell BS: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 1996, 56:2343-2347.
22. Freeman SM, McCune C, Robinson W: Treatment of ovarian cancer using a gene-modified vaccine. Hum Gene Ther 1995, 6:927-939.
23. Freeman SM, Whartenby KA, Freeman JL, Abboud CN, Marrogi AJ: In situ use of suicide genes for cancer therapy. Semin Oncol 1996, 23:31-45. An excellent review of the use of suicide genes in cancer therapy and a comprehensive listing of the clinical trials using suicide genes.
24. Hanania EG, Kavanagh J, Hortobagyi G, Giles RE, Champlin R, Deisseroth AB: Recent advances in the application of gene therapy to human disease. Am J Med 1995, 99:537-552. A review of current gene therapy protocols for the transfer of HSV-tk into tumors, the transfer of drug resistance genes into hematopoietic cells, and the generation of cancer vaccines.
25. Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, Stingl G, Birnstiel ML, Schweighoffer T: Priming of tumor specific T cells in the draining lymph nodes after immunization with interleukin 2 secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc Natl Acad Sci U S A 1995, 52:5540-5544. This paper suggests a three-stage process for formation of tumor-specific T cells after vaccination, in which antigen-presenting cells take up the tumor antigen at the site of injection, T cells in the draining lymph nodes are primed, and the activated T cells are circulated to elicit the tumorigenic response.
26. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, Sobol RE: Cytokine gene therapy with interleukin-2-transduced fibroblasts. Hum Gene Ther 1995, 6:591-601.
27. Vieweg J, Boczkowski D, Roberson KM, Edwards DW, Philip M, Philip R, Rudoll T, Smith C, Robertson C, Gilboa E: Efficient gene transfer with adeno-associated virus based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995, 55:2366-2372.
28. Philip R, Clary B, Brunette E, Kilinski L, Murugesh D, Sorich M, Yau J, Lebkowski J, Lyerly HK, Philip M: Gene modification of primary tumor cells for active immunotherapy of human breast and ovarian cancer. Clin Can Res 1996, 2:59-68.
29. Hurford RK Jr, Dranoff G, Mulligan RC, Tepper RI: Gene therapy of metastatic cancer by in vivo retroviral gene targetting. Nature Genet 1995, 10:430-435.
30. Minamoto S, Treisman J, Hankins WD, Sugamura K, Rosenberg SA: Acquired erythropoietin responsiveness of Interleukin 2 dependent T lymphocytes retrovirally transduced with genes encoding chimeric erythropoietin/interleukin 2 receptors. Blood 1995, 86:2281-2287. A paper describing the construction of a chimeric molecule that allows interleukin-2 stimulatory effects in T cells by Epo treatment, without inducing the toxicity observed in the presence of high levels of interleukin-2.
31. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995, 55:3369-3373. This paper describes the creation of T cells expressing the variable chain of the folate binding protein antibody linked to the T-cell receptor signaling chains, which leads to antigen-specific T-cell activation.
32. Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS, Ansel JC: Antitumor effects of granulocyte-macrophage colony stimulating factor production by melanoma cells. Cancer Res 1996, 56:2191-2198.
33. Zhang J-F, Hu C, Geng Y, Selm J, Klein SB, Orazi A, Taylor MW: Treatment of a human breast cancer xenograft with an adenovirus vector containing an Interferon gene results In rapid regression due to viral analysis and gene therapy. Proc Natl Acad Sci U S A 1996, 93:4513-4518.
34. Abe J, Wakimoto H, Tsunoda R, Okabe S, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H: In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus mediated genetic transduction. Biochem Biophys Res Commun 1996, 218:164-170.
35. Walther W, Stein U, Pfeil D: Gene transfer of human TNF alpha into glioblastoma cells permits modulation of MDR1 expression and potentiation of chemosensitivity. Int J Cancer 1995, 61:832-839.
36. Tos AG, Cignetti A, Rovera G, Foa R: Retroviral vector mediated transfer of the tumor necrosis factor alpha gene into human cancer cells restores an apoptotic cell death program and induces a bystander-killing effect Blood 1996, 87:2486-2495. This paper describes the induction of apoptosis in tumors transduced with TNF-α and the resulting bystander effect upon nearby untransduced tumor cells, which was neutralized by treatment with an α-TNF-α antibody.
37. Hallahan DE, Mauceri HJ, Seung LP, Dunphy EJ, Wayne JD, Hanna NN, Toledano A, Hellman S, Kufe DW, Weichselbaum RR: Spatial and temporal control of gene therapy using ionizing radiation. Nat Med 1995, 1:786-791.
38. Suzuki T, Tahara H, Narula S, Moore KW, Robbins PD, Lotze MT: Viral IL-10, the human herpes virus 4 cellular IL-10 homologue, induces local energy to allogeneic and syngeneic tumors. J Exp Med 1995, 182:477-486. A description of the effects of viral interleukin-10 on suppression of the immune response.
39. Gerard CM, Bruyns C, Delvaux A, Baudson N, Dargent JL, Goldman M, Velu T: Loss of tumorigenicity and increased immunogenicity induced by interleukin-10 gene transfer in B16 melanoma cells. Hum Gene Ther 1996, 7:23-31.
40. Lebel-Binay S, Laguerre B, Quintin-Colonna F, Conjeaud H, Magazin M, Miloux B, Pecceu F, Caput D, Ferrara P, Fradelizi D: Experimental gene therapy of cancer using tumor cells engineered to secrete interleukin-13. Eur J Immunol 1995, 25:2340-2348.
41. Tahara H, Zitvogel L, Storkus WJ, Zeh HJ, McKinney TG, Schreiber RD, Gubler U, Robbins PD, Lotze MT: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995, 154:6466-6474. A paper demonstrating efficient production of interleukin-12 and antitumor effects after transduction of the p35 and p40 subunits.
42. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL: Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996, 7:333-342.
43. Fujii H, Inobe M, Kimura F, Murata J, Murakami M, Onishi Y, Azuma I, Uede T, Saiki I: Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the anti-metastatic effect and tumor immunity in mice. Int J Cancer 1996, 66:219-224.
44. Cavallo F, Martin-Fontecha A, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G: Coexpression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995, 25:1154-1162.
45. Cayeux S, Beck C, Aicher A, Dorken B, Blankenstein T: Tumor cells co-transfected with interleukin 7 and B7-1 genes induce CD25 and CD28 on tumor infiltrating T lymphocytes and strong vaccines. Eur J Immunol 1995, 25:2325-2331.
46. + tumor cells are potent vaccines for stimulating tumor rejection in tumor bearing mice. J Exp Med 1995, 181:619-629. A paper demonstrating efficient tumor rejection after transduction with genes encoding syngeneic major histocompatibility complex class II and B7-1.
47. Yang C, Cirielli C, Capogrossi MC, Passaniti A: Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res 1995, 55:4210-4213.
48. Hamade K, Alemny R, Zhang WW, Hihelman WN, Lotan R, Roth JA, Mitchell MF: Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res 1996, 56:3047-3054. A paper showing the relationship between transduction efficiency and multiplicity of infection of adenoviral vectors.
49. Clayman GL, el-Naggar AK, Roth JA, Zhang WW, Goepfert H, Taylor DL, Liu TJ: In vivo molecular therapy with p53 adenovirus for microscopic residual head and neck squamous carcinoma. Cancer Res 1995, 55:1-6.
50. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A: Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 1996, 155:753-756.
51. Cirielli C, Riccioni T, Yang C, Pili R, Gloe T, Chang J, Inyaku K, Passaniti A, Capogrossi MC: Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. Int J Cancer L1995, 63:673-679.
52. Santoso JT, Tang DC, Lane SB, Hung J, Reed DJ, Muller CY, Carbone DP, Lucci JA III, Miller DS, Mathis JM: Adenovirus-based p53 gene therapy in ovarian cancer. Gynecol Oncol 1995, 59:171-178.
53. Gjerset PA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H, Hopkins PJ: Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 1995, 14:275-285.
54. Badie B, Drazan KE, Kramar MH, Shaked A, Black KL: Adenovirus-mediated p53 gene delivery inhibits 9L glioma growth in rats. Neurol Res 1995, 17:209-216.
55. Runnebaum IB, Kreienberg R: p53 Trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy. Hybridoma 1995, 14:153-157. A measurement of retroviral-mediated transduction efficiency, an important parameter in gene therapy.
56. Rosenfeld MR, Meneses P, Dalmau J, Drobnjak M, Cordon-Cardo C, Kaplitt MG: Gene transfer of wild-type p53 results in restoration of tumor-suppressor function in a medulloblastoma cell line. Neurology 1995, 45:1533-1539.
57. Lesoon-Wood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ: Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. Hum Gene Ther 1995, 6:395-405. In vivo injection of p53 liposomes, resulting in a reduction in size of primary tumors and prevention of relapse and metastasis of breast tumor.
58. Seth P, Brinkmann U, Schwartz GN, Katayose D, Gress R, Pastan I, Cowan K: Adenovirus-mediated gene transfer to human breast tumor cells: an approach for cancer gene therapy and bone marrow purging. Cancer Res 1996, 56:1346-1351. This paper presents a model demonstrating that the low efficiency of transduction of adenoviral vectors into bone marrow is useful for selective purging of metastatic breast cancer cells from the bone marrow.
59. Li J, Hu S-X, Xu K, Perng G-S, Zhang C, Benedict WF, Xu H-J: Effects of expression of the retinoblastoma (Rb) and p53 tumor suppressor genes on tumor cell invasion in vitro. Proc Am Assoc Cancer Res 1995, 36:78a.
60. Dawson DW, Tolsma SS, Volpert OV, Polverini PJ, Bouck NP: Retinoblastoma gene expression alters angiogenic phenotype. Proc AACR 1995, 36:88a.
61. Lu Y, Ussery GD, Muncaster MM, Gallie BL, Blanck G: Evidence for retinoblastoma protein (Rb) dependent and independent IFN-gamma responses: Rb coordinately rescues IFN-gamma induction of MHC class II gene transcription in noninducible breast carcinoma cells. Oncogene 1994, 9:1015-1019.
62. Xu H-J, Zhou Y, Seigne J, Perng G-S, Mixon M, Zhang C, Li J, Benedict WF, Hu S-X: Enhanced tumor suppresor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res 1996, 56:2245-2249.
63. Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang WW, Harper JW, et al.: In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995, 55:5151-5155. A comparison of the effectiveness of p53 or p21 gene transfer into prostate cancer cells.
64. Chang MW, Barr E, Lu MM, Barton K, Leiden JM: Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J Clin Invest 1995, 96:2260-2268. This paper suggests that the effectiveness of p21 gene transfer in vascular smooth muscle cells is due to regulation of the retinoblastoma phosphorylation state.
65. s is shown to have potential use in the gene therapy of human breast tumors.
66. Aksentijevich I, Cardarelli CO, Pastan I, Gottesman MM: Retroviral transfer of the human MDR1 gene confers resistance to bisantrene-specific hematotoxicity. Clin Cancer Res 1996, 2:973-980.
67. Licht T, Aksentijevich I, Gottesman MM, Pastan I: Efficient expression of functional human MDR1 gene in murine bone marrow after retroviral transduction of purified hematopoietic stem cells. Blood 1995, 86:111-121.
68. Ward M, Pioli P, Ayello J, Reiss R, Urzi G, Richardson C, Hesdorffer C, Bank A: Retroviral transfer and expression of the human multiple drug resistance (MDR) gene in peripheral blood progenitor cells. Clin Cancer Res 1996, 2:873-876.
69. Richardson C, Bank A: Preselection of transduced murine hematopoietic stem cell populations leads to increased long-term stability and expression of the human multiple drug resistance gene. Blood 1995, 86:2579-2589. This study presents a method to generate high in vivo expression of the MDR gene without in vivo drug treatment and may be important to the enrichment of cells expressing nonselectable genes.
70. Schwarzenberger P, Spence S, Lohrey N, Kmiecik T, Longo DL, Murphy WJ, Ruscetti FW, Keller JR: Gene transfer of multidrug resistance into a factor-dependent human hematopoeitic cell line: in vivo model for genetically transferred chemoprotection. Blood 1996, 87:2723-2731. A study of in vivo human hematopoietic cell drug resistance in the NOD-severe combined immunodeficient model.
71. Sugimoto Y, Aksentijevich I, Murray GJ, Brady RO, Pastan I, Gottesman MM: Retroviral coexpression of a multidrug resistance gene (MDR1) and human alpha-galactosidase A for gene therapy of Fabry disease. Hum Gene Ther 1995, 6:905-915.
72. Sokolic RA, Sekhsaria S, Sugimoto Y, Whiting-Theobald N, Linton GF, Li F, Gottesman MM, Malech HL: A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood 1996, 87:42-50.
73. Doroshow JH, Metz MZ, Matsumoto L, Winters KA, Sakai M, Muramatsu M, Kane SE: Transduction of NIH 3T3 cells with a retrovirus carrying both human MDR1 and glutathione S-transferase pi produces broad range multidrug resistance. Cancer Res 1995, 55:4073-4078. A proof-of-concept study demonstrating that cells transduced with two drug resistance genes possess broad-range drug resistance, and that selection for one gene increases activity of the second resistance gene.
74. Baum C, Hegewisch-Becker S, Eckert HG, Stocking C, Ostertag W: Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995, 69:7541-7547.
75. Aksentijevich I, Pastan I, Lunardi-Iskandar Y, Gallo RC, Gottesman MM, Thierry AR: In vitro and in vivo liposome-mediated gene transfer leads to human MDR1 expression in mouse bone marrow progenitor cells. Hum Gene Ther 1996, 7:1111-1122.
76. Flasshove M, Banerjee D, Bertino JR, Moore MA: Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant Leukemia 1995, 9:S34-37.
77. + peripheral blood progenitor cells after introduction of a mutated dihydrofolate reductase cDNA via retroviral gene transfer. Blood 1995, 85:566-574.
78. Spencer HT, Sleep SEH, Rehg JE, Blakley RL, Sorrentino BP: A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 1996, 87:2579-2587. Cells can become resistant to methotrexate through alteration of folate active transport mechanisms, but cells cannot acquire similar resistance to trimetrexate (TMTX) owing to the passive cellular entry of this drug. To overcome TMTX-induced myelosuppresssion, the L22Y DHFR mutant is used to provide increased TMTX resistance in transduced hematopoietic cells.
79. Allay JA, Dumenco LL, Koç ON, Liu L, Gerson SL: Retroviral transduction and expression of the human alkyltransferase cDNA provides nitrosourea resistance to hematopoietic cells. Blood 1995, 85:3342-3351. A thorough study of in vitro and in vivo resistance conferred to hematopoietic progenitors after MGMT gene transfer.
80. Moritz T, Mackay W, Glassner BJ, Williams DA, Samson L: Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and In vivo. Cancer Res 1995, 55:2608-2614.
81. Maze R, Carney JP, Kelley MR, Glassner BJ, Williams DA, Samson L: Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alklyating agent Proc Natl Acad Sci U S A 1996, 93:206-210.
82. 6-alkylguanine-DNA-alkyltransferase. Blood 1996, 87:1957-1961.
83. 6-benzylguanine and nitrosurea treatment.
84. 6-benzylguanine resistance in human hematopoletic progenitors [abstract]. Proc Am Assoc Cancer Res 1996, 37:334a.
85. Letourneau S, Greenbaum M, Cournoyer D: Retrovirus-mediated gene transfer of rat glutathione S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoeitic progenitor cells. Hum Gene Ther 1996, 7:831-840.
86. Koç ON, Allay JA, Lee KM, Davis BM, Reese JS, Gerson SL: Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance. Semin Oncol 1996, 23:46-65. A comprehensive review of the applications of drug resistance gene transfer for gene therapy.